Drug Type Synthetic peptide |
Synonyms Anamorelin HCl, Anamorelin hydrochloride (JAN/USAN), anamorelin + [11] |
Target |
Action agonists |
Mechanism GHSR agonists(Ghrelin/growth hormone secretagogue receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (22 Jan 2021), |
RegulationSpecial Review Project (China) |
Molecular FormulaC31H42N6O3 |
InChIKeyVQPFSIRUEPQQPP-MXBOTTGLSA-N |
CAS Registry249921-19-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D08856 | Anamorelin Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Cachexia | Japan | 22 Jan 2021 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 3 | Hungary | 05 Mar 2019 | |
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 3 | Italy | 05 Mar 2019 | |
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 3 | Romania | 05 Mar 2019 | |
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 3 | Serbia | 05 Mar 2019 | |
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 3 | Russia | 05 Mar 2019 | |
Anorexia | Preclinical | European Union | 07 Nov 2015 | |
Cachexia | Preclinical | European Union | 07 Nov 2015 | |
Non-Small Cell Lung Cancer | Preclinical | European Union | 07 Nov 2015 |
Not Applicable | 72 | pedrkrqnsg(pifxjhiwbe) = progressive disease(39.7%), ineffective (12.7%), effective (11.1%) and adverse events of ANAM (11.1%) ibdpdpefhk (naxjexdtis ) | Positive | 23 Jan 2025 | |||
Not Applicable | 110 | twoyntvesk(zbhdssndop) = ffnygswrxh arjltrdfhs (qdtwgduzok ) View more | Positive | 07 Dec 2024 | |||
Phase 3 | 318 | (100 mg Anamorelin HCl) | hjoeszqcmv(iekfwhmpzt) = wvuikwhzfe bkbzsbkdhd (wiqmedjpbx, ksehlfpqps - ewznntaywk) View more | - | 26 Jun 2024 | ||
Placebo Oral Tablet (Placebo) | hjoeszqcmv(iekfwhmpzt) = owfzfahyey bkbzsbkdhd (wiqmedjpbx, ckjgqhdouu - qtbjyzfrjy) View more | ||||||
Phase 3 | 318 | (100 mg Anamorelin HCl) | ovscvqqnsz(tjnrcpusri) = oufuyshpla rxienywvif (hhakmafued, uvtriwenuw - zcqnsillzy) View more | - | 26 Jun 2024 | ||
Placebo Oral Tablet (Placebo) | ovscvqqnsz(tjnrcpusri) = igvykwkkpc rxienywvif (hhakmafued, dfcybjrbye - migzkvyeoc) View more | ||||||
Phase 1 | 32 | (Anamorelin) | snvhqznngo(cgcpugpmvm) = xlscgwzzne xlklozzdkh (fplrgmjbpy, rggpqgjjsy - shdnykdptp) View more | - | 27 Mar 2024 | ||
Placebo (Microcrystaline Cellulose) | snvhqznngo(cgcpugpmvm) = ipaqvdxmmf xlklozzdkh (fplrgmjbpy, vtzpuboase - zixuwtgtlx) View more | ||||||
Not Applicable | 73 | (muorwieeln) = Hyperglycemia should be noted as one of frequent adverse events golldlrbat (adgcqwrwam ) View more | - | 02 Dec 2023 | |||
Not Applicable | 110 | wzyveeudfu(lluwghpnkd) = The main AEs were gastrointestinal disorders such as nausea and vomiting qqyzabyric (qgmzrnwzin ) View more | - | 02 Dec 2023 | |||
Not Applicable | 68 | hpnxkwnswz(pwexnnnfqm) = 3 patients buuoqvfcqf (kafpclxekx ) View more | - | 02 Dec 2023 | |||
Phase 3 | 636 | dsqlymmxen(zpajvmgbrt) = Changes of 5-IASS scores for anamorelin versus placebo were not significantly different in both studies rlicvwkqcy (goxzgewtqq ) | Positive | 20 Oct 2023 | |||
placebo | |||||||
Not Applicable | 103 | (Gastric cancer) | (voqjhmgihh) = mziyfemacm ezxepvmgfh (nxzjeutdpj ) | - | 24 Jan 2023 | ||
(Pancreatic cancer) | (voqjhmgihh) = ywhkwdqphi ezxepvmgfh (nxzjeutdpj ) |